VISUfarma B.V.

VISUfarma B. V. is a Netherlands-based company that develops and markets specialized ophthalmic products aimed at improving eye health and treating conditions such as Dry Eye Syndrome and glaucoma. Founded in 2016 in Amsterdam, Netherlands, VISUfarma focuses on the development of innovative ophthalmic solutions.

The company, led by CEO Fabrizio Giombini, was founded by Thomas Van Haarlem. It has not undergone any significant pivots or changes in its operational strategy since inception, nor does it have known subsidiaries or a parent company. VISUfarma specializes in ophthalmic products aimed at enhancing eye health, particularly for conditions like Dry Eye Syndrome and glaucoma. Its flagship product, TREHAPAN®, provides long-lasting protection for patients with dry eye, while VisuXL® Gel caters to those with more severe symptoms.

The company targets healthcare professionals, including eye care specialists, pharmacies, and hospitals, primarily within Europe and North America, thereby playing a crucial role in managing chronic eye conditions. In the most recent fiscal year, VISUfarma reported an EBITDA of -7015115 EUR. The company operates on a B2B model, generating revenue through direct sales of specialized ophthalmic products, predominantly TREHAPAN® and VisuXL® Gel, to healthcare providers, eye care specialists, and pharmacies. Revenue generation is enhanced through bulk purchasing agreements and long-term partnerships with healthcare professionals, ensuring a consistent demand for their products.